Clinigen Group Plc (CLIGF) Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research upgraded shares of Clinigen Group Plc (NASDAQ:CLIGF) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. They currently have $15.00 target price on the stock.
According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
Clinigen Group Plc (NASDAQ CLIGF) opened at 13.90 on Wednesday. Clinigen Group Plc has a 52 week low of $8.70 and a 52 week high of $13.90. The company has a market cap of $1.60 billion and a PE ratio of 85.28.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/clinigen-group-plc-cligf-upgraded-to-buy-by-zacks-investment-research/1533701.html.
Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.